Home » Newsletters » BioWorld Science

BioWorld Science

March 5, 2013

View Archived Issues

Ascorbix presents novel agents for cancer

Italian researchers patent new photosensitizing agents

Suzhou NeuPharma discloses novel arctigenin derivatives for cancer

HSCI obtains approval in Ukraine for Neovasculgen

Biosantech initiates phase I/II trial of synthetic AIDS vaccine Tat Oyi

Activin betaC expression plays a role in the progression of prostate disease

HAT-01: a novel herbal preparation for the treatment of atopic dermatitis

Katanin enzyme complexes necessary for male fertility

UCB reflects on achievements of 2012

Researchers at Ascendis Pharma synthesize novel prodrugs of paliperidone

Promethera Biosciences opens French site in phase I/II HepaStem trial

BioLineRx's candidate for severe and persistent asthma to enter main pipeline

Novan Therapeutics reports preclinical data for topical sebum inhibitor

Trophos confirms positive interim review for pivotal olesoxime trial

Life Technologies signs stem cell research agreement

NIBP expression shows partial correlation with breast tumor staging

FDA accepts filing of BLA for recombinant factor IX Fc fusion protein

FDA agrees with La Jolla Pharmaceutical's proposed IND for LJPC-501

Immuron reports preclinical data for IMM-529

Sarepta Therapeutics reports data from non-human primate study of AVI-7288

VX-787 shows antiviral activity in phase II influenza challenge study

EMA grants orphan drug status to Prothena's candidate for amyloid light-chain amyloidosis

Researchers at Merck KGaA design new RON inhibitors

HH1.5 shows potential as a novel biomarker in prostate cancer

Verona's RPL-554 demonstrates anti-inflammatory activity in exploratory trial

Health Canada declines to approve Theratechnologies' NDS for Egrifta

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...